Lelystad, the Netherlands – November 20th 2020 – Pepscan, the all-in-one peptide service provider with proprietary peptide constraining technologies, today announced that it has entered into a global agreement with Bicycle Therapeutics plc regarding the use of Pepscan’s CLIPS peptide technology for the further development of Bicycle’s product candidates BT1718 and THR-149.
As expert in constrained peptides, Pepscan developed a proprietary, highly versatile constraining technology to lock peptides into active conformations, called CLIPS (Chemical Linkage of Peptides onto Scaffolds). The CLIPS cyclization technology is known for its versatility and ease of application. CLIPS-peptides are recognized for their enhanced affinity, selectivity and proteolytic stability.
Peter Timmerman, CSO and inventor of the CLIPS technology: “We are proud to grant Bicycle a license for the continued use of the CLIPS technology for BT1718 and THR-149”. As part of the agreement, Pepscan and Bicycle have agreed to settle all intellectual property disputes worldwide.
About Pepscan
Pepscan is the all-in-one peptide service provider,
building on 25 years of experience in advancing and applying peptide
expertise to facilitate clients in the development and (GMP) production
of peptides. At its end-to-end facility in Lelystad, the Netherlands,
Pepscan offers a range of patented technologies, phage display
capabilities, a lead-optimization array platform, and production
facilities for R&D- to GMP-grade peptides, including libraries and
neoantigen vaccines. Among its patents is the CLIPS technology, which
locks peptides into active conformations. With its epitope mapping
service platform, Pepscan also supports biotech companies in developing
their antibody pipelines. The underlying protein mimicry platform
delivers binding insights, even in cases where other technologies fall
short. For more information visit pepscan.com.